New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names Ozempic and Wegovy, has been hailed as a miracle drug for ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Novo Nordisk shares fell ... An earlier study of the drug late last year disappointed investors with the weight-loss it achieved, wiping out nearly $100 billion of the drugmaker's stock-market ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names ... According to Goldman Sachs, the market for GLP-1 drugs is expected to reach $100 billion by 2030. Indian companies are gearing ...